Slides
Page 1
Q2 FY 26-27 Investor Presentation November 2026
Page 2
Disclaimer 2 Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Akums Drugs and Pharmaceuticals Limited. All information contained in this presentation has been prepared solely by Akums Drugs and Pharmaceuticals Limited. Akums Drugs and Pharmaceuticals Limited does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith.
Page 3
We are pleased to announce the results for Q2 FY27 and H1 FY27. During Q2, we enhanced the results achieved during Q1. During Q2, the revenue grew by more than 30% and EBITDA more than doubled YoY. Even sequentially i.e. QoQ, the revenue growth was at an impressive 15% and EBITDA increased by 11.5%. The growth was spearheaded by the CDMO segment with double digit volume growth and improvement in API prices. The demand environment for CDMO remains robust and Akums continues to deepen its presence within the IPM. Our domestic branded formulations segment had a steady quarter with 8% YoY growth in revenue and marked improvement in profitability on a sequential basis. Our international branded formulations business saw growth accelerating, both on YoY and QoQ basis. API segment continued on its journey towards achieving EBITDA break even as our endeavours continued. The trade generic segment cemented EBITDA positivity during the quarter. Our European CDMO project is progressing as per plan and we continue to make steady progress vis-à-vis our Zambia initiative with commercial supplies from the Indian plant scheduled during Q4 FY27 with revenue booking expected in Q1 FY 28. We are proud to announce that Akums earned an EcoVadis Bronze Medal, placing us among Top 35% of global assessed companies. We remain optimistic of delivering positive results and remain committed to creating long term shareholder value - Sanjeev Jain & Sandeep Jain Managing Directors’ Message Dear Investors 3
Page 4
Plant 1 ,2 & 3 received EU- GMP accreditation Listed on NSE and BSE Started new injectable and a new OSD facility ANVISA certified for Plant 3 Incorporated in April 2004 Set up of first plant for oral solid dosage form in Haridwar. Established dedicated manufacturing site for Oral Liquid Dosage & Sterile products. Established a nutraceutical facility Expanded into Asian markets. Established R&D lab in Mumbai to venture into regulated market. Received US-NSF Certification for Maxcure Nutravedicsfacility Dedicated facilities for Hormones, Cosmetics and Dermatology. Launched Akumentisto venture into branded formulations. Started dedicated plant for β-lactam anti- infectives and steroids Acquired Parabolic Drugs to venture intoAPI More than Two Decades’ Legacy of Expertise, Experience & Trust 4 Set up dedicated facility for Penems at Kotdwar Acquired 2 plants in Cosmetics and nutraceuticals
Page 5
5 Technologically Advanced Manufacturing Capabilities (1/2) Location YEAR CAPACITY¹ CAPABILITY DOSAGE FORMS Haridwar 2004 649 General 1 Haridwar 2007 15 General 2 Haridwar 2007 39 General 3 Haridwar 2010 264 Hormonal 1 3 4 Haridwar 2010 6 Cosmetics 4 Haridwar 2010 269 Ayurvedic / Nutraceuticals 1 2 Haridwar 2014 2,635 General 1 2 3 4 DOSAGE FORM 1 Oral solid 2 Oral liquid 3 Injectable / sterile 4 External / topical ¹ Annual capacity in Cr units
Page 6
6 Technologically Advanced Manufacturing Capabilities (2/2) PHOTO PHOTO Location YEAR CAPACITY¹ CAPABILITY DOSAGE FORMS Haridwar 2014 732 β-lactams & steroids 1 2 3 4 Kotdwar 2021 17 Penem anti-infective 1 2 3 Baddi 2023 392 General 1 2 Haridwar 2024 41 General 3 Roorkee 2026 13 Cosmeceuticals 4 Noida 2026 7 Cosmeceuticals 4 Baddi# 2027 - General QUALITY CREDENTIALS* *Received by some or all facilities; # upcoming facility; ¹ Annual capacity in Cr units 1 1 DOSAGE FORM 1 Oral solid 2 Oral liquid 3 Injectable / sterile 4 External / topical
Page 7
Financial Performance Highlights Q2/H1 FY 27 7
Page 8
Key drivers and their impact on Akums’ performance Strong CDMO volume growth momentum continues API prices saw an increase in Q2 API segment continues on its path to profitability Marketing segments profitability improved sequentially Akums continued to witness double digit volume growth leading to healthy capacity utilization over 50%. API prices momentum sustained in Q2 albeit at a lower pace. API losses curtailed significantly. International and domestic branded segments margins remained lower YoY however, improved sequentially. Trade generics continues to break even. 9 Key drivers as well as their trends during Q2 FY27
Page 9
Q2 FY27 Performance Highlights 9 Business Vertical Share in revenue CDMO 83.1% Domestic Branded Formulation 9.8% International Branded Formulation 3.3% API 2.1% Trade Generics 1.7% Segment Break-upConsolidated Performance 1,050 cr Total Income (+0.3% YoY) 121 cr 11.6% Adj. EBITDA (-130 bps YoY) 54 cr 5.1% Adj. PAT (-57 bps YoY) 1,371 cr Total Income (+30.6% YoY) 224 cr 16.3% EBITDA (including other income) (+76.3% YoY) Operating Performance 1,342 cr Revenue (+31.9% YoY) 195 cr 14.5% EBITDA (+106.1% YoY) 115 cr 8.4% PAT (+168.3% YoY) 115 cr 8.4% PAT (+168.3% YoY) 9
Page 10
H1 FY27 Performance Highlights 10 Business Vertical Share in revenue CDMO 82.9% Domestic Branded Formulation 9.9% International Branded Formulation 3.1% API 2.4% Trade Generics 1.8% Segment Break-upConsolidated Performance 1,050 cr Total Income (+0.3% YoY) 121 cr 11.6% Adj. EBITDA (-130 bps YoY) 54 cr 5.1% Adj. PAT (-57 bps YoY) 2,568 cr Total Income (+22.3% YoY) 429 cr 16.7% EBITDA (including other income) (+51.7% YoY) Operating Performance 2,509 cr Revenue (+22.9% YoY) 369 cr 14.7% EBITDA (+65.3% YoY) 216 cr 8.4% PAT (+100.7% YoY) 216 cr 8.4% PAT (+100.7% YoY) 10
Page 11
Profit and Loss Statement 11 11 Particulars (Rs Cr) Q2 FY27 Q2 FY26 Y-O-Y (%) Q1 FY27 Q-O-Q (%) H1 FY 27 H1 FY 26 Y-O-Y (%) FY26 Revenue 1,342 1,018 31.9% 1,167 15.1% 2,509 2,042 22.9% 4,359 COGS 767 593 29.4% 645 18.8% 1,412 1,174 20.2% 2,514 GP Margin % 42.9% 41.8% 44.7% 43.7% 42.5% 42.3% Employee Expenses 224 189 18.5% 201 11.3% 426 365 16.5% 754 Other Expenses 157 141 10.9% 145 8.0% 302 278 8.5% 570 EBITDA 195 94 106.1% 175 11.5% 369 223 65.3% 522 EBITDA Margin % 14.5% 9.3% 15.0% 14.7% 10.9% 12.0% Finance Cost 26 23 10.2% 25 3.7% 50 46 8.6% 94 Depreciation & Amort. 43 38 14.1% 41 5.2% 84 75 12.7% 155 Exceptional Expenses - - - - - - - - 20 Other Income 29 32 (10.7)% 30 (4.9)% 59 59 0.3% 129 Profit Before Tax 155 66 135.6% 139 11.1% 294 161 82.2% 382 Tax 40 23 74.9% 38 5.0% 78 54 45.4% 126 PAT 115 43 168.3% 101 13.5% 216 107 100.7% 256 PAT Margin % 8.4% 4.1% 8.4% 8.4% 5.1% 5.7% EPS 7.37 2.66 176.7% 6.53 12.8% 13.90 6.81 104.1% 16.67
Page 12
Quarterly Performance Trends Revenue (INR Cr.) EBITDA (INR Cr) 13.1%12.7% Margin % 15.0% 14.5%9.3% PAT (INR Cr) 6.8%5.7% Margin % 8.4% 8.4%4.1% 12 168.3 %106.1% 94 147 152 175 195 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 31.9% 1,018 1,160 1,158 1,167 1,342 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 43 68 81 101 115 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27
Page 13
HY Performance Trends Revenue (INR Cr.) EBITDA (INR Cr) 10.9%10.4% Margin % 12.9% 14.7%12.0% PAT (INR Cr) 5.1%10.3% Margin % 6.2% 8.4%6.2% 13 100.7 %65.3% 245 215 223 299 369 H1 FY25 H2 FY25 H1 FY26 H2 FY26 H1 FY27 22.9% 2,052 2,066 2,042 2,317 2,509 H1 FY25 H2 FY25 H1 FY26 H2 FY26 H1 FY27 128 216 107 149 216 H1 FY25 H2 FY25 H1 FY26 H2 FY26 H1 FY27
Page 14
© 2025 All Rights Reserved. Private Limited 14 Half-Yearly Performance Highlights Working Capital Days Operating Cash Flow (INR Cr)# Return Ratios* Net WC 91 105 98 1,152 1,181 256 198 227 256 H1 FY26 FY26 H1 FY27 OCF Adj OCF Adj OCF/EBITDA % 88.7% 43.5% 69.2% 6.8% 7.7% 12.2%13.1% 14.6% 19.4% 13.0% 14.3% 22.2% H1 FY26 FY26 H1 FY27 ROE ROCE ROIC 67 67 63 76 71 82 100 110 117 H1 FY26 FY 26 H1 FY 27 Debtors Creditors Inventory *Half yearly figures are annualized; #Adj OCF/EBITDA (including other income) for FY 26 was 34.9%
Page 15
Revenue and Margin Deep-Dive – Quarterly 15 Revenue (INR Cr.) EBITDA % • Other exp and employee exp benefitted from operating leverage • GM improvement led by CDMO and API segments • Revenue growth driven by CDMO • International branded formulation showed healthy growth on weak base • Reduction in API and Trade generics in line with expectation
Page 16
Revenue and Margin Deep-Dive – Half Yearly 16 Revenue (INR Cr.) EBITDA % • Other exp and employee exp benefitted from operating leverage • GM improvement led by CDMO and API segments • Revenue growth driven by CDMO • International branded formulation showed healthy growth on lower base • Reduction in API and Trade generics in line with expectation
Page 17
17 Segmental Quarterly Performance CDMO Revenue Domestic Branded Formulation Revenue International Branded Formulation Revenue Trade Generics Revenue API Revenue CDMO EBITDA 17.0%10.5% 15.1% Margin % Trade Generics EBITDA API EBITDA Domestic Branded Formulation EBITDA 21.6% 10.3% 18.2% International Branded Formulation EBITDA 24.5% 19.9% 22.6% 804 964 1,115 Q2 FY26 Q1 FY27 Q2 FY27 122 115 132 Q2 FY26 Q1 FY27 Q2 FY27 22 35 44 Q2 FY26 Q1 FY27 Q2 FY27 84 163 168 Q2 FY26 Q1 FY27 Q2 FY27 24 21 23 Q2 FY26 Q1 FY27 Q2 FY27 26 12 24 Q2 FY26 Q1 FY27 Q2 FY27 44 32 29 Q2 FY26 Q1 FY27 Q2 FY27 5 7 10 Q2 FY26 Q1 FY27 Q2 FY27 -3 0.1 1.2 Q2 FY26 Q1 FY27 Q2 FY27 -14 -4 -6 Q2 FY26 Q1 FY27 Q2 FY27 38.6%YoY15.6%QoQ 8.2%YoY14.4%QoQ 95.2%YoY26.7%QoQ -5.4%YoY10.1%QoQ -35.3%YoY-9.1%QoQ
Page 18
18 Segmental HY Performance CDMO Revenue Domestic Branded Formulation Revenue International Branded Formulation Revenue Trade Generics Revenue API Revenue CDMO EBITDA 12.6% 16.0% Margin % Trade Generics EBITDA API EBITDA Domestic Branded Formulation EBITDA 18.4% 14.5% International Branded Formulation EBITDA 23.5% 21.4% 1,618 2,079 H1 FY26 H1 FY27 229 247 H1 FY26 H1 FY27 57 78 H1 FY26 H1 FY27 204 332 H1 FY26 H1 FY27 48 44 H1 FY26 H1 FY27 42 36 H1 FY26 H1 FY27 89 60 H1 FY26 H1 FY27 14 17 H1 FY26 H1 FY27 -8 1 H1 FY26 H1 FY27 -20 -10 H1 FY26 H1 FY27 28.5%YoY 7.8%YoY 36.2%YoY -7.4%YoY -32.5%YoY
Page 19
Annexures 19
Page 20
Abbreviations and Definitions 20 Abbreviations • CDMO: Contract development and manufacturing organization • API: Active Pharmaceutical Ingredient • EBITDA: Earnings before interest, depreciation and tax • EBIT: Earnings before interest and tax • PBT: Profit before Tax • PAT: Profit after tax • NOPAT :Net operating profit after tax • OCF: Operating cash flow • EPS: Earnings per share • Net WC: Net Working capital • ROE: Return on Equity • ROCE: Return on capital employed • ROIC :Return on invested capital • Adj: Adjusted • INR: Indian Rupee • Cr: Crore • EU: Europe Definitions • Net WC: Debtor days + Inventory days – Creditor days • ROE: PAT/ Total Equity • ROCE: (EBIT + Other Income)/Capital Employed • EBIT: EBITDA – depreciation and amortization • Capital Employed: Total Equity + Borrowings • ROIC: NOPAT/ Invested Capital • Tax rate: Total Tax exp / PBT • NOPAT: EBIT * (1-Tax rate) • Invested Capital: Capital Employed–Cash and cash equivalents • Adj OCF: OCF – 954 cr advance received in FY 26 20
Page 21
Thank You For further information, contact: 21 IR Desk Akums Drugs and Pharmaceuticals Ltd Email: investors@akums.net/ankit.jain@akums.net